| Name | Title | Contact Details |
|---|---|---|
Petteri Arola |
Chief Information Security Officer | Profile |
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.
We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
Diana Plants Sciences (Diana Group) is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMedica, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.